PROVERA (medroxyprogesterone acetate) by Pfizer is (mpa) inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. First approved in 1959.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
Provera (medroxyprogesterone acetate) is an oral progestin tablet approved since 1959 for contraception and hormone-related indications. It works by inhibiting gonadotropin secretion, preventing follicular maturation and ovulation while thickening cervical mucus. The drug represents a foundational hormonal contraceptive in the oral contraceptive market.
Product approaching loss of exclusivity with minimal Part D utilization signals a mature, generic-vulnerable franchise requiring defensive commercial strategy rather than growth investment.
(MPA) inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. These actions contribute to its contraceptive effect.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age
Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers
Comparative Bioavailability of Two Injectable Suspension Formulations of Medroxyprogesterone Acetate+Estradiol Cypionate
Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood
Worked on PROVERA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moZero linked job openings indicate minimal active hiring for Provera-dedicated roles, reflecting portfolio maturity and approaching LOE. Career value lies primarily in defensive brand management, generic strategy, and portfolio transition planning rather than growth-stage visibility.